Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 22 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consun Pharma's reported carbon emissions
In 2023, Consun Pharma reported total carbon emissions of approximately 79,256,220 kg CO2e, comprising 54,210,460 kg CO2e from Scope 1 emissions and 24,914,760 kg CO2e from Scope 2 emissions. The Scope 1 emissions included 435,640 kg CO2e from mobile combustion and 1,454,670 kg CO2e from fugitive emissions. For Scope 2, the majority of emissions, about 9,587,400 kg CO2e, were attributed to purchased electricity. Comparatively, in 2022, the company recorded total emissions of about 72,337,200 kg CO2e, with Scope 1 emissions at 53,214,680 kg CO2e and Scope 2 emissions at 18,842,520 kg CO2e. This indicates a slight increase in emissions from 2022 to 2023. Consun Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of defined reduction strategies suggests a need for further development in their sustainability practices. The company has consistently reported emissions data for Scope 1 and Scope 2 but has not provided information on Scope 3 emissions. Overall, while Consun Pharma has made strides in transparency regarding their emissions, the lack of reduction targets highlights an opportunity for enhanced climate action and commitment to sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 735,000 | 000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 7,104,000 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
